<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04970329</url>
  </required_header>
  <id_info>
    <org_study_id>TUF/MPO/2102</org_study_id>
    <nct_id>NCT04970329</nct_id>
  </id_info>
  <brief_title>Corneal Thickness Changes in Patient Undergoing Dry Eye Managment</brief_title>
  <official_title>Corneal Thickness Changes in Patient Undergoing Dry Eye Managment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Faisalabad</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Faisalabad</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to the determine effect of dry eye and to compare the effect&#xD;
      of artificial tears on central and peripheral corneal thickness.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this randomized controlled trial, 96 eyes of females with dry eye will be recruited&#xD;
      through random sampling. Dry eye assessments will be done including TBUT, Schirmer test 1,&#xD;
      and OSDI questionnaire. 96 eyes will be divided into 3 groups (32 eyes each) and will be&#xD;
      provided intervention which is Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. , Dextran&#xD;
      0.1%Hypromellose 0.3%, and placebo(normal saline) through randomization by an unmasked&#xD;
      investigator. Changes in central and peripheral corneal thickness will be evaluated by&#xD;
      corneal topography. Patients will be evaluated at baseline, after 15 days, after 1 month, and&#xD;
      re-evaluated after 1 month of cessation of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>96 eyes will be divided into 3 groups (32 eyes each) and will be provided intervention which is Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. , Dextran 0.1%Hypromellose 0.3%, and placebo(normal saline)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Both participant and investigator will be masked about the treatment options.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Corneal Thickness in microns</measure>
    <time_frame>one month</time_frame>
    <description>effect of dry eye treatment on the thickness of the cornea in microns measured by using corneal topography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Corneal Thickness in microns after treatment discontinuation.</measure>
    <time_frame>one month</time_frame>
    <description>after on month of treatment discontinuation access the change in corneal thickness in microns by using corneal topography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in dry eye</measure>
    <time_frame>one month</time_frame>
    <description>after treatment with artifical tears improvement in the tear break-up time in seconds and schirmer test values in millimeters.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>Systane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Instill one drop three times a day for one month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tears Naturale 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Instill one drop three times a day for one month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Instill one drop three times a day for one month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. and Dextran 0.1%Hypromellose 0.3%,</intervention_name>
    <description>Drugs will be given to two group and third group will kept on placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Systane</arm_group_label>
    <arm_group_label>Tears Naturale 2</arm_group_label>
    <other_name>Systane and Tears Naturale 2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        ● Females with ages ranging between 18-40 years and OSDI scores greater than 13, ametropia&#xD;
        of up to 1DS of SE with astigmatism of less than 0.5DC, and Emmetropes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refractive error of more than ±1 Ds of SE and astigmatism of greater than ±0.5DC.&#xD;
&#xD;
          -  Corneal surface disease other than dry eye disease.&#xD;
&#xD;
          -  Corneal ectasia.&#xD;
&#xD;
          -  Corneal or eyelid infections&#xD;
&#xD;
          -  Age &lt; 18 and &gt;40 years.&#xD;
&#xD;
          -  History of contact lens wears within the past three months.&#xD;
&#xD;
          -  Male will be excluded because sex has a large influence on the symptomatology of DED&#xD;
             Males have significantly low symptom scores as compared to females.&#xD;
&#xD;
          -  Corneal surgeries.&#xD;
&#xD;
          -  History of ocular /systemic disease within the past 6 months.&#xD;
&#xD;
          -  The patients already receiving any kind of treatment for DED and other ocular&#xD;
             diseases.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Dry eye has more prevalence in females.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Komal Atta, mbbs</last_name>
    <phone>03224075007</phone>
    <email>komal.atta@tuf.edu.pk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fatima Iqbal, m.phil od</last_name>
    <phone>03315538865</phone>
    <email>fatima.iqbal@tuf.edu.pk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Faisalabad</name>
      <address>
        <city>Faisalabad</city>
        <state>Punjab</state>
        <zip>3800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <contact>
      <last_name>Fatima Iqbal, Mphill</last_name>
      <phone>03315538865</phone>
      <email>fatima.iqbal@tuf.edu.pk</email>
    </contact>
    <contact_backup>
      <last_name>Komal Atta, MBBS</last_name>
      <phone>03224075007</phone>
      <email>komal.atta@tuf.edu.pk</email>
    </contact_backup>
    <investigator>
      <last_name>Fatima Hussain, Mphill</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 10, 2021</study_first_submitted>
  <study_first_submitted_qc>July 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Faisalabad</investigator_affiliation>
    <investigator_full_name>Fatima Hussain</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dextrans</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

